Its anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases.

Since 2013, the company has been wholly-owned by Novo Holdings A/S, which is also a major shareholder in Danish diabetes care giant Novo Nordisk.